Calidi Biotherapeutics (CLDI)CEO sold ~$16K
Allan Camaisa, CEO at Calidi Biotherapeutics, sold ~$16K of Calidi Biotherapeutics shares.
- ~$16K
- Approx. value · 10K sh @ $1.62
- 67K
- Holds after · shares reported
- Traded
- Dec 17, 2024
- Filed
- Dec 19, 2024
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Calidi Biotherapeutics
OQRO holds no insider, Congress, fund or contract record for Calidi Biotherapeutics dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its CLDI page.
Other recent filings by Allan Camaisa, CEO and Chairman of the Board
The full history of Allan Camaisa, CEO and Chairman of the Board is on the profile page.
How this filing works
Other disclosures at Calidi Biotherapeutics
- SEC Form 4Dec 17, 2025
- SEC Form 4Aug 26, 2025
- SEC Form 4Aug 26, 2025
- SEC Form 4Aug 26, 2025
- SEC Form 4Aug 26, 2025
Everything OQRO holds on this company is on its CLDI page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO Pro is a paid subscription. You see the price before you pay
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data